Biopharmaceutical News and Research

RSS

Bavarian Nordic updates on vaccine project pipeline

In a business update, Danish-based biopharmaceutical company Bavarian Nordic, reported a number of developments in its vaccine project pipeline.

6 Nov 2007

Combination targets offer new hope in fight against cancer

While some targeted therapies - drugs developed to attack specific molecules in the critical chemical pathways occurring within cancer cells - work well by themselves, increasingly researchers are finding that they work better when teamed with other targeted and conventional therapies.

24 Oct 2007

Orexigen presents findings on obesity drug candidates

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of central nervous system (CNS) disorders including obesity, has presented the results of a preclinical study that further supports the Company's understanding of an aspect of the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.

24 Oct 2007

New analyses of long-term LIALDA (mesalamine) data presented at ACG

Post-hoc and other analyses of secondary endpoints of a long-term safety and tolerability study of Shire plc's ulcerative colitis (UC) drug LIALDA (mesalamine) provide further data on LIALDA in patients with mild to moderate ulcerative colitis.

16 Oct 2007

Biopharmaceutical infrastructure key to lower drug development costs

Improvements to the technology infrastructure for researching and developing new biopharmaceuticals would be expected to save the industry hundreds of millions of dollars annually, according to a new economic study sponsored by the National Institute of Standards and Technology (NIST).

12 Oct 2007

Aida granted new anti-cancer patent

One of mainland China's leading pharmaceutical companies, has announced that it was granted an additional patent related to its Rh-Apo2L anti-cancer drug, the second of three patents that had been applied for which Aida believes places it at the vanguard of China's pharmaceutical industry.

12 Oct 2007

Wyeth Pharmaceuticals to acquire Haptogen

Wyeth Pharmaceuticals, a division of Wyeth has announced the signing of a definitive agreement under which it has acquired Haptogen Ltd., a Scottish company based in Aberdeen that is focused on the discovery of biopharmaceutical therapies.

8 Oct 2007

Blood protein detects lung cancer, even at earliest stage

Biopharmaceutical researchers have found a protein in blood they say is linked to all stages of lung cancer but which rarely shows up in the blood of people without the disease.

18 Sep 2007

New green methods for coating drugs in plastics

Green chemistry is being employed to develop revolutionary drug delivery methods that are more effective and less toxic - and could benefit millions of patients.

13 Sep 2007

New drugs to combat bioterrorism

The University of Illinois at Chicago College of Pharmacy has received a grant from the U.S. Department of Defense to develop new drugs to combat agents of bioterrorism.

7 Aug 2007

New strategy for treating allergic disorders

Ghent - Oral intake of allergens or auto-antigens via the lactic acid bacterium Lactococcus lactis might be a new strategy for treating various kinds of auto-immune and allergic disorders.

2 Aug 2007

Schering-Plough announces licensing of Acadesine

Schering-Plough Corporation has announced the worldwide licensing of acadesine, an investigational, potentially first-in-class adenosine regulating agent (ARA), from PeriCor Therapeutics, Inc., a privately held, specialty biopharmaceutical company.

20 Jul 2007

Cancer survivors share their advice in new book

Few chemotherapy patients would think to decorate their bald heads with stickers of bowling balls, or of bunny rabbits saying, "Wish you were hare."

18 Jul 2007

Roche and Alnylam form RNAi therapeutics alliance

Roche and the US-based biopharmaceutical company Alnylam Pharmaceuticals, Inc. announced today that they have entered into a major alliance in which Roche obtains a non-exclusive license to Alnylam's technology platform for developing RNAi (RNA interference) therapeutics.

9 Jul 2007

Experimental Alzheimer's drug begins clinical trials

A drug based on the design of a Purdue University researcher to treat Alzheimer's disease began the first phase of human clinical trials this week.

23 Jun 2007

Arpida receives FDA approval to initiate Phase II trial with intravenous iclaprim

Arpida Ltd. has announced that it has received approval from the US Food and Drug Administration for a Phase II trial with intravenous iclaprim in the treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare-associated pneumonia (HCAP) suspected or confirmed to be due to Gram-positive pathogens.

23 Jun 2007